Literature DB >> 32701922

COVID-19: new scenario old problems.

Francesco Auxilia1, Anna Maraschini2, Patrizia Bono3, Riccardo Ungaro4, Ester Luconi5, Elia Biganzoli6, Silvana Castaldi7.   

Abstract

The short paper present the problem of hospital acquired infection in subintensive units og a research and teaching hospital.

Entities:  

Mesh:

Year:  2020        PMID: 32701922      PMCID: PMC8023089          DOI: 10.23750/abm.v91i9-S.10119

Source DB:  PubMed          Journal:  Acta Biomed        ISSN: 0392-4203


The Corona Virus 19 (COVID-19) epidemic is an infectious disease which was declared as a pandemic and hit all the Countries, all over the world, from the beginning of the year 2020 (1). In Italy the epidemic started in Lombardia Region and then it circulated all over the Country and at the moment (30.06.2020) there are 239.709 confirmed cases, 33.542 deaths with 14% as case fatality rate (2,3). As it was recorded from the beginning of this epidemic up to now almost 10% of patients with COVID-19 experiments an hospital admission and 9% of them needs to stay in intensive care units but the numbers were very different at the beginning of the epidemic when the patients with critical conditions were much more (2). In a research and teaching hospital located in the centre of Milan to face the sudden flow of critical ill COVID 19 patients many beds were turned in intensive and sub intensive care ones, in particular 84 subintensive beds out of the active 716 beds were set up to admit patients who needed less intensive care than in the intensive care units. In total from March 9th to June 6th 2020, 246 patients were admitted to these 84 beds for sub intensive care and 80 of whom perished (data from the hospital administrative records). During their stay in hospital these patients, as all the others, faced also a considerable threat for their safety caused by healthcare associated infections (HAIs) which might have determined adverse clinical outcomes (4-8). All these 246 patients were routinely followed with the usual local infection control surveillance program to detect colonization by multidrug-resistant bacteria, namely MRSA (Methicillin-resistant Staphylococcus aureus), multidrug-resistant Gram-negative bacteria and VRE (Vancomycin-resistant enterococci) in addiction received all the microbiological investigation in case of infectious symptoms. Globally, 751 swabs for surveillance program were performed and 90 were found positive in 73 patients. Among these, 14 patients had more than one positive swab in different body sites (namely nose and rectum) with different bacteria species. In particular 35 swabs were positive for VRE and 16 for an extended spectrum beta-lactamase (ESBL) Escherichia coli. Of the 938 cultures performed for clinical purposes in symptomatic patients, 186 resulted positive belonging to 74 patients. Thirty eight patients were diagnosed with an infective episode during hospitalization, 13 with 2 and 12 with 3. The most common isolated pathogens were Enterococcus faecalis, Staphylococcus epidermidis (29 cases each) and Escherichia coli (22 cases). These first results showed how management of COVID-19 can often be complicated with the emergence of colonization with drug-resistant bacteria and with nosocomial infections, which can lead to aggressive antimicrobial therapies with further resistance selection (9,10). In our hospital the medical team for HAIs prevention decided against implementing an antibiotic empirical approach for COVID patients, however it must be considered that most of these patients were hospitalized in intensive care units where the odd to receive an antimicrobical therapy is high. Currently, an universal, safe, effective and targeted treatment for COVID-19 is lacking. More over COVID-19 patients are at high risk of HAIs so their care must be transversal and multidisciplinary and the use and selection of antibiotics should be weighed to prevent resistance selection (10). In any case these patients must considered very frail and must be protect with a very high standard of environmental hygiene and clinical performance (10).
  8 in total

1.  Hospital Hygiene and Infection Prevention and Control in Italy: state of the art and perspectives.

Authors:  S Brusaferro; L Arnoldo; G Finzi; I Mura; F Auxilia; C Pasquarella; A Agodi
Journal:  Ann Ig       Date:  2018 Sep-Oct

2.  Control of scabies outbreaks in an Italian hospital: an information-centered management strategy.

Authors:  Matteo Capobussi; Giuliana Sabatino; Annalisa Donadini; Carlo A Tersalvi; Silvana Castaldi
Journal:  Am J Infect Control       Date:  2014-03       Impact factor: 2.918

3.  Epidemiology of Clostridium difficile-associated disease in internal medicine wards in northern Italy.

Authors:  Luca Mellace; Dario Consonni; Gaia Jacchetti; Marta Del Medico; Riccardo Colombo; Marta Velati; Simone Formica; Maria Domenica Cappellini; Silvana Castaldi; Giovanna Fabio
Journal:  Intern Emerg Med       Date:  2012-01-17       Impact factor: 3.397

4.  Risk factors and epidemiology of Acinetobacter baumannii infections in a university hospital in Northern Italy: A case-control study.

Authors:  I Ardoino; F Zangirolami; D Iemmi; M Lanzoni; M Cargnelutti; E Biganzoli; S Castaldi
Journal:  Am J Infect Control       Date:  2016-06-17       Impact factor: 2.918

5.  Antibiotic resistance: Italian awareness survey 2016.

Authors:  Anna Prigitano; Luisa Romanò; Francesco Auxilia; Silvana Castaldi; Anna M Tortorano
Journal:  J Infect Public Health       Date:  2017-03-09       Impact factor: 3.718

6.  Knowledge, experiences, and attitudes toward Mantoux test among medical and health professional students in Italy: a cross-sectional study.

Authors:  M T Montagna; S Mascipinto; C Pousis; F P Bianchi; G Caggiano; L F Carpagnano; O De Giglio; G Barbuti; F Auxilia; A Destrebecq; S Castaldi; T Baldovin; A Bargellini; E Righi; G Boccia; E Santoro; B Casini; A Baggiani; R Novati; R Oriani; A Odone; A G Mezzoiuso; G B Orsi; C Napoli; C Pasquarella; L Veronesi; G Ripabelli; M L Sammarco; A Rossini; R Squeri; P Laganà; G M Antonuccio; C Genovese; S Tardivo; I Torre; R Alfano; F Pennino; M V Torregrossa; M Barchitta; A Agodi
Journal:  Ann Ig       Date:  2018 Sep-Oct

7.  Impact of multi-drug resistant bacteria on economic and clinical outcomes of healthcare-associated infections in adults: Systematic review and meta-analysis.

Authors:  Miquel Serra-Burriel; Matthew Keys; Carlos Campillo-Artero; Antonella Agodi; Martina Barchitta; Achilleas Gikas; Carlos Palos; Guillem López-Casasnovas
Journal:  PLoS One       Date:  2020-01-10       Impact factor: 3.240

8.  Heterogeneity of COVID-19 outbreak in Italy.

Authors:  Bruno Alessandro Rivieccio; Ester Luconi; Patrizia Boracchi; Elena Pariani; Luisa Romanò; Silvia Salini; Silvana Castaldi; Elia Biganzoli; Massimo Galli
Journal:  Acta Biomed       Date:  2020-04-20
  8 in total
  4 in total

1.  Management of chronic patients during the COVID-19 pandemic: the experience of a referral center for rare hematological disorders in the hardest-hit region in Italy.

Authors:  Giovanna Graziadei; Marina Baldini; Irene Motta; Alessia Marcon; Maria Domenica Carrabba; Elena Cassinerio; Margherita Migone De Amicis; Adriana Branchi; Marianna Giuditta; Diletta Maira; Giovanna Fabio
Journal:  Ann Hematol       Date:  2021-02-02       Impact factor: 3.673

2.  The identity of public health in COVID-19 times.

Authors:  Anna Odone; Marco Vitale; Carlo Signorelli
Journal:  Acta Biomed       Date:  2020-07-20

3.  COVID-19: What happened to the healthcare workers of a research and teaching hospital in Milan, Italy?

Authors:  Dario Consonni; Lorenzo Bordini; Carlo Nava; Aldo Todaro; Giovanna Lunghi; Andrea Lombardi; Davide Magioni; Francesco De Palo; Lidia Guerrieri; Michele Gatti; Daniele Serra; Marco Polonioli; Simone Pratò; Antonio Muscatello; Alessandra Bandera; Francesco Auxilia; Silvana Castaldi
Journal:  Acta Biomed       Date:  2020-09-07

4.  Hospital Acquired Infections in COVID-19 patients in sub intensive care unit.

Authors:  Silvana Castaldi; Ester Luconi; Giuseppe Marano; Francesco Auxilia; Anna Maraschini; Patrizia Bono; Riccardo Ungaro; Alessandra Bandera; Patrizia Boracchi; Elia Biganzoli
Journal:  Acta Biomed       Date:  2020-09-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.